Product Information
QUETIAPINE FUMARATE 300 MG TAB is a generic product labeled by Rising Pharma Holdings Inc., priced at $0.1275 per EA under NDC 16571072110. Its NADAC has been published 240 times since Mar 2, 2022.
FDA first approved this application on Mar 27, 2012. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
300 mg/1
Manufacturer
Rising Pharma Holdings Inc.NDC
16571072110
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
QUETIAPINE FUMARATEApproval Type
Generic (ANDA)
FDA Application
ANDA091388FDA Approved
3/27/2012
TE Code
AB
On Market Since
3/27/2012
Pharmacological Classes
Price Statistics
The NADAC for QUETIAPINE FUMARATE 300 MG TAB has been published 240 times since Mar 2, 2022, and over the history we have for it it has declined 27.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1275 per EA |
|---|---|
| All-time high | $0.1904 (Mar 13, 2024) |
| All-time low | $0.1136 (Nov 20, 2024) |
| 52-week high | $0.1465 |
| 52-week low | $0.1265 |
| Median price | $0.1408 |
| Average price | $0.1434 |
| Largest weekly change | -26.7% (Nov 20, 2024) |
| Weeks tracked | 240 |
| Tracking since | Mar 2, 2022 |
Generic Alternatives
The matcher finds 7 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rising Pharma Holdings Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Quetiapine Fumarate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Atypical Antipsychotic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of QUETIAPINE FUMARATE 300 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for QUETIAPINE FUMARATE 300 MG TAB, manufactured by Rising Pharma Holdings Inc., is $0.1275 per EA (NDC 16571072110), effective Sep 30, 2026.
How has the price of QUETIAPINE FUMARATE 300 MG TAB changed over time?
Over the history we have for it, the NADAC for QUETIAPINE FUMARATE 300 MG TAB has declined 27.3%. It has been tracked across 240 weekly CMS publications since Mar 2, 2022.
What are the highest and lowest recorded NADAC prices for QUETIAPINE FUMARATE 300 MG TAB?
Since Mar 2, 2022, the NADAC for QUETIAPINE FUMARATE 300 MG TAB has ranged from a low of $0.1136 (Nov 20, 2024) to a high of $0.1904 (Mar 13, 2024), with a median of $0.1408 per EA.
Are there cheaper alternatives to QUETIAPINE FUMARATE 300 MG TAB?
7 manufacturers publish a NADAC-priced product with the same active ingredient and strength as QUETIAPINE FUMARATE 300 MG TAB in a comparable dosage form, but none are currently priced below it.
Who manufactures QUETIAPINE FUMARATE 300 MG TAB?
QUETIAPINE FUMARATE 300 MG TAB (NDC 16571072110) is labeled by Rising Pharma Holdings Inc., and CMS classifies it as a generic product.